Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between phenobarbital and thioridazine.

P E Gay, J A Madsen

    Neurology
    |December 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Thioridazine (TDZ) significantly reduces serum phenobarbital (PB) levels in individuals, suggesting a dose-dependent interaction. However, TDZ did not consistently affect serum phenytoin (PHT) levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Endothelial cell growth factor enhances musculocutaneous flap survival through the process of neovascularization.

    Annals of plastic surgery·1999
    Same author

    Biliary tract obstruction secondary to mycosis fungoides: a case report.

    Journal of clinical gastroenterology·1999
    Same author

    Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life.

    The Journal of pediatrics·1998
    Same author

    Neoplasia in ileal pouch mucosa after total proctocolectomy for juvenile polyposis: report of a case.

    Diseases of the colon and rectum·1997
    Same author

    Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

    Psychological reports·1995
    Same author

    Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.

    Cancer immunology, immunotherapy : CII·1995
    Same journal

    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

    Neurology·2026
    Same journal

    Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

    Neurology·2026
    Same journal

    Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

    Neurology·2026
    Same journal

    Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

    Neurology·2026
    Same journal

    Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

    Neurology·2026
    Same journal

    At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

    Neurology·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Clinical Pharmacy

    Background:

    • Antiepileptic drugs (AEDs) like phenobarbital (PB) and phenytoin (PHT) are crucial for managing epilepsy.
    • Drug interactions can alter AED efficacy and patient safety, necessitating careful monitoring.
    • Thioridazine (TDZ), an antipsychotic, has potential for interactions with other medications.

    Purpose of the Study:

    • To investigate the impact of thioridazine (TDZ) on serum levels of phenobarbital (PB) and phenytoin (PHT) in individuals with intellectual disabilities.
    • To determine if TDZ alters the steady-state serum concentrations of PB and PHT when co-administered.

    Main Methods:

    • A case-control study design was employed, matching individuals on TDZ with controls receiving only AEDs.
    • Participants were matched based on age, sex, body weight, and AED dosage.

    Related Experiment Videos

  • Trough, steady-state serum levels of PB and PHT were measured during routine monitoring.

    • Main Results:

    • Concomitant administration of TDZ (100-200 mg/day) resulted in significantly lower serum PB levels per unit dose compared to PB alone.
    • The observed reduction in PB levels appeared to be responsive to the TDZ dosage.
    • Thioridazine (TDZ) did not demonstrate consistent effects on serum PHT levels.

    Conclusions:

    • Thioridazine (TDZ) exhibits a dose-dependent interaction that reduces serum phenobarbital (PB) levels.
    • Clinicians should be aware of this interaction when prescribing TDZ concurrently with PB.
    • Further research may be warranted to elucidate the mechanism of this interaction and its clinical implications for PHT.